{"companyId":290652,"requestedLanguage":"ja","resolvedLanguage":"ja","availableLanguages":["en","fr","ja"],"companyName":"Poxel株式会社","headOfficeLocation":"フランス・リヨン","presidentName":null,"companySummary":null,"stockCode":"POXEL","currency":"EUR","capital":null,"sales":null,"employees":null,"employeesConsolidated":null,"humanCheck":false,"domains":["www.poxelpharma.com"],"businessContents":["臨床段階のバイオ医薬品企業","代謝機能障害関連脂肪肝炎（MASH）の治療法開発","副腎白質変性症（ALD）や常染色体優性遺伝性疾患などの希少疾患治療法開発","PXL065（重水素安定化R-ピオグリタゾン）の開発","PXL770（直接的AMPK活性化剤）の開発","2型糖尿病のためのTWYMEEG®（イメグリミン）の開発","日本におけるイメグリミンのための住友ファーマとの戦略的パートナーシップ"],"relations":[{"detailNumber":1,"relationCompanyName":"Sumitomo Pharma","relationCompanyId":null,"url":null,"linkUrl":null,"remarks":"候補複数(社名部分一致):20","lastCheckDate":"2026-10-14","raGroup":0,"raParent":0,"raChild":0,"raCustomer":50,"raSupplier":0,"raPartnership":0,"raFinance":0,"raInvest":0}],"dataSources":[{"detailNumber":1,"url":"https://www.poxelpharma.com/en_us/investors/company-information/profile","scoreAbout":101,"scoreBusiness":18,"scoreGroup":6,"scoreCustomer":3},{"detailNumber":2,"url":"https://www.poxelpharma.com/","scoreAbout":0,"scoreBusiness":66,"scoreGroup":47,"scoreCustomer":0},{"detailNumber":3,"url":"https://www.poxelpharma.com/fr","scoreAbout":0,"scoreBusiness":50,"scoreGroup":52,"scoreCustomer":52}]}